European Journal of Clinical Microbiology & Infectious Diseases (2019) 38:1151–1152
https://doi.org/10.1007/s10096-019-03553-8

PUBLISHER CORRECTION

Correction to: In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing *Klebsiella pneumoniae* isolated in Greek hospitals in 2015–2016

Irene Galani[1,2] · Maria Souli[1] · Konstantina Nafplioti[1] · Panagiora Adamou[1] · Ilias Karaiskos[3] · Helen Giamarellou[3] · Anastasia Antoniadou[1] · On Behalf Of The Study Collaborators

Published online: 29 April 2019

Publisher Correction: European Journal of Clinical Microbiology & Infectious Diseases
https://doi.org/10.1007/s10096-019-03517-y

The publisher regrets that the article has been published online on 01 March 2019 with errors in Table 1.

In the originally published Table 1, the percentage of Imipenem-relebactam susceptibility was incorrectly written as 8 0, while correct data is 98.0. Also, in Meropenem row, column MIC_{50} (mg/L), the incorrect data 4 should be 64.

Subsequently, the revised Table 1 with the corrected data is shown below.

The original article has been corrected.

The online version of the original article can be found at https://doi.org/10.1007/s10096-019-03517-y

✉ Irene Galani
egalani@med.uoa.gr

[1] 4th Department of InternalMedicine, Infectious Diseases Laboratory, Molecular Biology Section, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

[2] University General Hospital "ATTIKON", Rimini 1, 124 62 Chaidari, Greece

[3] 1st Internal Medicine & Infectious Diseases Clinic, Hygeia General Hospital, Marousi, Greece

Table 1 MIC and cumulative percent inhibited distributions for imipenem-relebactam and comparators, in relation to the carbapenemase type produced by the 314 *K. pneumoniae* isolates

Organism /Genotype	Agent	No of isolates / (cumulative % of isolates) inhibited at MIC (mg/L)										MIC_{50} (mg/L)	MIC_{90} (mg/L)	S (%)
		≤0.25	0.5	1	2	4	8	16	32	64	>64			
KPC-producers (n=295)	Imipenem					2 (0.7)	28 (10.2)	74 (35.3)	47 (**51.2**)	109 (88.1)	35 (100)	32	>64	0
	Imipenem-relebactam	**154 (52.2)**	**91 (83.1)**	**29 (92.9)**	**15 (98.0)**	6 (100)						0.25	1	98.0
	Meropenem				**1 (0.3)**		22 (7.8)	41 (21.7)	60 (42.0)	44 (56.9)	127 (100)	64	>64	0.3
	Doripenem				3 (1.0)	28 (10.5)	58 (30.2)	32 (41.0)	39 (54.2)	72 (78.6)	63 (100)	32	>64	0
	Colistin		**28 (9.5)**	**133 (54.6)**	**18 (60.7)**	9 (63.7)	11 (67.5)	18 (73.6)	41 (87.5)	21 (94.6)	16 (100)	1	64	63.4
	Fosfomycin					**1 (0.3)**	**13 (4.7)**	**74 (29.8)**	**87 (59.3)**	58 (79.0)	62 (100)	32	1024	59.3
	Tigecycline	**3 (1.0)**	**37 (13.6)**	**103 (48.5)**	114 (87.1)	31 (97.6)	5 (99.3)	2 (100)				2	4	48.5
	Gentamicin		**6 (2.0)**	**51 (19.3)**	**132 (64.1)**	41 (78.0)	5 (79.7)	13 (84.1)	4 (85.4)	5 (87.1)	38 (100)	2	>64	64.1
	Ceftazidime-avibactam	**20 (6.8)**	**83 (34.9)**	**130 (79.0)**	**52 (96.6)**	**9 (99.7)**		1 (100)				1	2	99.7
OXA-producers[a] (n=19)	Imipenem					6 (31.6)	10 (84.2)	2 (94.7)			1 (100)	8	16	0.0
	Imipenem-relebactam				**2 (10.5)**	13 (78.9)	2 (89.5)	1 (94.7)	1 (100)			4	16	10.5
	Meropenem						1 (5.3)	9 (52.6)	7 (89.5)	1 (94.7)	1 (100)	16	64	0.0
	Doripenem						9 (47.4)	9 (94.7)			1 (100)	16	16	0.0
	Colistin		**1 (5.3)**	**7 (42.1)**					8 (84.2)	2 (94.7)	1 (100)	32	64	42.1
	Fosfomycin					**1 (5.3)**		**9 (52.6)**	**3 (68.4)**	1 (73.7)	5 (100)	16	>64	68.4
	Tigecycline		**3 (15.7)**	**9 (63.2)**	4 (84.2)	1 (89.5)	1 (94.7)				1 (100)	1	8	63.2
	Gentamicin			**2 (10.5)**	**2 (21.1)**				1 (26.3)		14 (100)	>64	>64	21.1
	Ceftazidime-avibactam		**7 (36.8)**	**10 (89.5)**	**2 (100)**							1	2	100.0

[a] One isolate harboring also bla_{KPC} is included

Bold indicates susceptible by EUCAST 2018 breakpoint